Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
Status:
RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). 12 participants will be enrolled and can expect to be on study for up to 12 months.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
National Cancer Institute (NCI) National Institute of Dental and Craniofacial Research (NIDCR)